drugset / Trial / NCT02938507

Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects

NCT02938507

Phase 1 Completed 24 enrolled Velicept Therapeutics, Inc.
RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of different formulations of orally administered solabegron in healthy male subjects.

Timeline

Start
2016-10
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Solabegron Unknown Oral

Indications